



Yes  
You  
Health

## Product list

July 2025

**Farmaprojects**  
*polpharma*  
GROUP

# Under development generics

| INN                                     | PHARMACEUTICAL FORM         | STRENGTH  | REFERENCE PRODUCT                       |
|---|-----------------------------|---|---|
| Alimentary tract & metabolism           |                             |   |   |
| Empagliflozin* / Metformin              | Film - coated tablets       | 5mg / 850mg 5mg / 1000mg 12.5mg / 850mg 12.5mg / 1000mg | Synjardy® / Boehringer Ingelheim        |
| Linagliptin* / Metformin                | Film - coated tablets       | 2.5mg / 500mg 2.5mg / 850mg 2.5mg / 1000mg <sup>o</sup> | Jentadueto® / Boehringer Ingelheim      |
| Allergy/Immuno                          |                             |   |   |
| Baricitinib                             | Film - coated tablets       | 2mg / 4mg   | Olumiaant® / Lilly                      |
| Upadacitinib                            | Prolonged - release tablets | 15mg / 30mg / 45mg                                      | Rinvoq® / Abbvie                        |
| Nervous System                          |                             |   |   |
| Ozanimod                                | Hard capsules               | 0,23mg / 0,46mg / 0,92mg                                | Zeposia® / BMS                          |
| Respiratory System                      |                             |   |   |
| Fluticasone / Vilanterol                | Inhalation powder           | 92mcg / 22mcg / 184mcg / 22mcg                          | Bro Ellipta® / GSK                      |
| Umeclidinium / Vilanterol               | Inhalation powder           | 55mcg / 22 mcg  | Anoro Ellipta® / GSK                    |
| Fluticasone / Umeclidinium / Vilanterol | Inhalation powder           | 100mcg / 74,2mcg / 62,5mcg 200mcg / 74,2mcg / 62,5mcg   | Trelegy Ellipta® / GSK                  |
| Cardiology                              |                             |   |   |
| Finerenone                              | Film-Coated Tablets         | 10mg / 20mg   | Kerendia® / Bayer                       |
| Bempedoic Acid                          | Film-Coated Tablets         | 180mg   | Nilemdo® / Daiichi Sankyo (Esperion)    |
| Bempedoic Acid / Ezetimibe              | Film-Coated Tablets         | 180mg / 10 mg   | Nustendi® / Daiichi Sankyo (Esperion)   |
| Anti-infectives for systemic use        |                             |   |   |
| Avibactam / Ceftazidime                 | Powder for Injection        | 500mg / 2g  | Zavicefta® / Pfizer (Abbvie / Allergan) |
| Short RNA (Oligonucleotide)             |                             |   |   |
| Nusinersen                              | Solution for injection      | 12 mg/5ml vial (2.4mg/ml)                               | Spinraza® (Biogen)                      |
| Inclisiran                              | Solution for injection      | 284 mg/1.5 mL prefilled syringe (189 mg/mL)             | Leqvio® (Novartis)                      |

\*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

# Under development value added

| INN                   | INDICATION                   | DEVELOPMENT PHASE    |
|-----------------------|------------------------------|----------------------|
| Cardiovascular System |                              |                      |
| CV31                  | Hypertension                 | Clinical development |
| CV22                  | Hypertension / Heart Failure | Lab development      |

## Available

| INN                             | PHARMA<br>CEUTICA<br>L FORM | STRENGTH                    | REFERENCE<br>PRODUCT                    | LACTOSE<br>FREE | STABILITY  | SHELF LIFE  |
|---------------------------------|-----------------------------|-----------------------------|---|-----------------|--|---|
| Alimentary tract & metabolism   |                             |                             |   |                 |  |   |
| Dapagliflozin*<br>/ MetforminCA | Film -<br>coated<br>tablets | 5mg / 850mg<br>5mg / 1000mg | Xigduo® /<br>AstraZeneca                | Yes             | II: on-going<br>IVa: ext. from<br>b IVb: on-<br>going        | 24 months (36 months in<br>Q3 2024) 24 months (36<br>months in Q3 2024) |
| Dapagliflozin*<br>CA            | Film -<br>coated<br>tablets | 5mg 10mg                    | Forxiga® /<br>AstraZeneca               | Yes             | II: on-going<br>IVa: ext. from<br>b IVb: on-<br>going        | 36 months 36 months   |
| Empagliflozin*<br>CA            | Film -<br>coated<br>tablets | 10mg 25mg                   | Jardiance® /<br>Boehringer<br>Ingelheim | Yes             | II: on-going<br>IVa: ext. from<br>b IVb: on-<br>going        | 36 months 36 months -<br>Not store above 30 oC                          |
| Linagliptin*CA                  | Film -<br>coated<br>tablets | 5mg                         | Trajenta® /<br>Boehringer<br>Ingelheim  | Yes             | II: on-going<br>IVa: ext. from<br>b IVb: on-<br>going        | 36 months 36 months   |
| Orlistat                        | Hard<br>capsules            | 120mg                       | Xenical® / Roche                        | Yes             | II: available<br>IVb: not<br>available                       | 24 months   |
| Orlistat OTC                    | Hard<br>capsules            | 60mg                        | Alli® / GSK                             | Yes             | II: available<br>IVa: not<br>available IVb:<br>not available | 24 months   |

\*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

|                          |                       |                               |                  |     |  |           |
|--------------------------|-----------------------|-------------------------------|------------------|-----|--|-----------|
| Sitagliptin*             | Film – coated tablets | 25mg 50mg<br>100mg            | Januvia® / Merck | Yes | II: available<br>IVa: not available IVb: available | 36 months |
| Sitagliptin* / Metformin | Film – coated tablets | 50mg / 850mg<br>50mg / 1000mg | Janumet® / Merck | Yes | II: available<br>IVa: not available IVb: available | 24 months |

### Anti-infectives for systemic use

|           |         |                      |                |     |  |           |
|-----------|---------|----------------------|----------------|-----|--|-----------|
| Aciclovir | Tablets | 200mg 400mg<br>800mg | Zovirax® / GSK | Yes | II: available<br>IVa: not available IVb: not available | 36 months |
|-----------|---------|----------------------|----------------|-----|--|-----------|

### Antineoplastic & Immunomodulating Agents

|               |                       |                   |                   |     |  |                       |
|---------------|-----------------------|-------------------|-------------------|-----|--|-----------------------|
| Apremilast*CA | Film – coated tablets | 10mg 20mg<br>30mg | Otezla® / Celgene | Yes | II: available<br>IVa: not available IVb: not available | 12 months (target 36) |
|---------------|-----------------------|-------------------|-------------------|-----|--|-----------------------|

### Blood & Blood forming organs

|                |                       |                         |                                 |     |  |           |
|----------------|-----------------------|-------------------------|---------------------------------|-----|--|-----------|
| Apixaban*      | Film – coated tablets | 2.5mg 5mg               | Eliquis® / Bristol-Myers Squibb | No  | II: available<br>IVa: ext. from b IVb: available | 36 months |
| Rivaroxaban*CA | Film – coated tablets | 2.5mg 10mg<br>15mg 20mg | Xarelto® / Bayer                | No  | II: on-going<br>IVa: ext. from b IVb: on-going   | 24 months |
| Rivaroxaban*   | Capsules              | 10mg 15mg<br>20mg       | Xarelto® / Bayer                | No  | II: on-going                                     | 24 months |
| Ticagrelor*    | Film – coated tablets | 60mg 90mg               | Brilique® / AstraZeneca         | Yes | II: available<br>IVa: ext. from b IVb: available | 36 months |

### Cardiovascular System

|                        |                                |  |                      |     |  |           |
|------------------------|--------------------------------|--|----------------------|-----|--|-----------|
| Ramipril / Indapamide  | Hard capsules (IR dosage form) | 5mg / 2.5mg<br>10mg / 2.5mg<br>5mg / 1.25mg<br>10mg / 1.25mg | New combination      | No  | II: on-going   | 36 months |
| Sacubitril / Valsartan | Film – coated tablets          | 49mg / 51mg<br>24mg / 26mg<br>97mg / 103mg                   | Entresto® / Novartis | Yes | II: available<br>IV: not available                     | 48 months |
| Hydrochlorothiazide*   | Tablets                        | 12.5mg 25mg<br>50mg  | Esidrex® / Novartis  | No  | II: available<br>IVa: not available IVb: not available | 60 months |

\*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

|                                      |   |  |  |   |  |   |
|--------------------------------------|---|--|--|---|--|---|
| Ramipril /<br>Amlodipine             | Hard<br>capsules                          | 5mg / 5mg<br>5mg / 10mg<br>10mg / 5mg<br>10mg / 10mg   | Tritace®<br>(Ramipril) /<br>Sanofi &<br>Norvasc®<br>(Amlodipine) /<br>Pfizer | Yes   | II: available<br>IVa: not<br>available IVb:<br>not available | 36 months   |
| Rosuvastatin                         | Film –<br>coated<br>tablets               | 5mg 10mg<br>20mg                                       | Crestor(TM) /<br>AstraZeneca   | No  | II: available<br>IVa: (12<br>months) IVb:<br>not available   | 36 months   |
| Telmisartan /<br>Amlodipine          | Bilayered<br>Tablets                      | 40mg / 5mg<br>40mg / 10mg<br>80mg / 5mg<br>80mg / 10mg | Twynsta® /<br>Boehringer<br>Ingelheim  | Yes   | II: available<br>IVa: ext. from<br>b IVb:<br>available       | 36 months   |
| Dermatologicals                      |   |  |  |   |  |   |
| Dimetindene                          | Gel                                       | 1mg /g (20g)<br>1mg /g (30g)<br>1mg /g (50g)           | Fenistil(TM) /<br>Novartis   | Yes   | II: available<br>IVa: ext. from<br>b IVb:<br>available       | 36 months   |
| Genito-Urinary System & Sex Hormones |   |  |  |   |  |   |
| Tadalafil*                           | Film –<br>coated<br>tablets               | 2.5mg 5mg<br>10mg 20mg                                 | Cialis® / Eli Lilly  | No  | II: available<br>IVa: ext. from<br>b IVb:<br>available       | 48 months   |
| Musculoskeletal System               |   |  |  |   |  |   |
| Paracetamol/<br>Ibuprofen            | Film –<br>coated<br>tablets               | 500 mg / 200<br>mg                                     | Nurofen Ultima®<br>/ Reckitt<br>Benckiser                                    | II: available<br>IVa: on-<br>going IVb:<br>on-going | 36 months  |   |
| Nervous System                       |   |  |  |   |  |   |
| Dimethyl<br>FumarateCA               | Gastro –<br>resistant<br>hard<br>capsules | 120mg 240mg  | Tecfidera® /<br>Biogen Idec  | Yes   | II: on-going<br>IVa: ext.from<br>b IVb: on-<br>going         | 36 months / do not store<br>above 30oC (zone II) 24<br>months / do not store<br>above 30oC (zone IVb) |
| Memantine<br>hydrochloride           | Film –<br>coated<br>tablets               | 10mg 20mg  | Ebixa® /<br>Lundbeck   | No  | II: available<br>IVa: available<br>IVb: no ext.<br>from a    | 36 months   |
| Quetiapine                           | Film-<br>coated<br>tablets                | 25mg / 100mg<br>150mg / 200mg<br>300mg                 | Seroquel® /<br>AstraZeneca   | No  | II: available<br>IVa: available<br>IVb: available            | 36 months   |
| Respiratory System                   |   |  |  |   |  |   |

\*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

|   |                            |   |                                      |     |  |  |
|---|----------------------------|---|--------------------------------------|-----|--|--|
| Xylomethazolin<br>e/<br>Dexpanthenol<br>OTC | Nasal<br>spray<br>solution | 1.0mg / 50mg /<br>ml (10ml) 0.5mg<br>/ 50mg / ml (10<br>ml) | Nasic(TM) /<br>Cassella-med          | Yes | II: available<br>IVa: ext. from<br>b IVb:<br>available | 24 months (0.5mg) 36<br>months (1.0mg) |
| Glycopyrronium                              | Inhalation<br>powder       | 44mcg   | Seebri<br>Breezhaler® /<br>Novartis  | No  | II: available  | 24 months                              |
| Glycopyrronium /<br>Indacaterol             | Inhalation<br>powder       | 43mcg /<br>85mcg  | Ultibro<br>Breezhaler® /<br>Novartis | No  | II: available<br>IVb: on-going                         | 24 months                              |
| Vitamins & Minerals                         |                            |   |                                      |     |  |  |
| Cholecalciferol<br>(Vitamin D3)             | Soft<br>capsule            | 20.000 IU   | N/A                                  | Yes | II: available<br>IVa: not<br>available                 | 36 months                              |

\*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.



FARMAPROJECTS SAU  
Carrer Provença 392, 6ª Planta  
08025 Barcelona (Spain)  
Phone +34 93 508 05 00  
email: sales@farmaprojects.com

[www.farmaprojects.com](http://www.farmaprojects.com)

